Literature DB >> 6362711

Oral administration of cyclosporin A for recipients of allogeneic marrow transplants: implications of clinical gut dysfunction.

K Atkinson, J C Biggs, K Britton, R Short, R Mrongovius, A Concannon, A Dodds.   

Abstract

Cyclosporin A (CyA) was used to minimize graft-versus-host disease (GVHD) in 28 recipients of allogeneic marrow transplants. When given orally, the absorption of CyA was markedly dependent on normal gut function. Patients without gut dysfunction showed normal serum concentration-time curves while those with diarrhoea from any cause (chemo-radiation enteritis, acute GVHD of the gut, infectious enteritis) showed minimal absorption of the drug. These data indicate the desirability of the intravenous administration of CyA during periods of gut dysfunction in marrow transplant recipients.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6362711     DOI: 10.1111/j.1365-2141.1984.tb03950.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  13 in total

Review 1.  Pharmacokinetic drug interactions with cyclosporin (Part II).

Authors:  G C Yee; T R McGuire
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

Review 2.  Clinically significant drug interactions with cyclosporin. An update.

Authors:  C Campana; M B Regazzi; I Buggia; M Molinaro
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

3.  Pharmacodynamics of T cell function for monitoring pharmacologic immunosuppression after allogeneic hematopoietic stem cell transplantation.

Authors:  Carmen Martínez; Olga Millán; Montserrat Rovira; Francesc Fernández-Avilés; Anna López; María Suárez-Lledó; Enric Carreras; Álvaro Urbano-Ispízua; Mercè Brunet
Journal:  Int J Hematol       Date:  2016-11-23       Impact factor: 2.490

4.  Distribution and concentration of cyclosporin in human blood.

Authors:  K Atkinson; K Britton; J Biggs
Journal:  J Clin Pathol       Date:  1984-10       Impact factor: 3.411

5.  The absorption site of cyclosporin in the human gastrointestinal tract.

Authors:  J Drewe; C Beglinger; T Kissel
Journal:  Br J Clin Pharmacol       Date:  1992-01       Impact factor: 4.335

6.  Cyclosporine pharmacokinetic profiles in liver, heart, and kidney transplant patients as determined by high-performance liquid chromatography.

Authors:  G J Burckart; R Venkataramanan; R J Ptachcinski; T E Starzl; B P Griffith; T R Hakala; J T Rosenthal; R L Hardesty; S Iwatsuki; J Brady
Journal:  Transplant Proc       Date:  1986-12       Impact factor: 1.066

7.  Acute folic acid deficiency after bone marrow transplantation.

Authors:  H Link; M Blaurock; P Wernet; D Niethammer; K Wilms; P Ostendorf
Journal:  Klin Wochenschr       Date:  1986-05-02

Review 8.  Clinical pharmacokinetics of cyclosporin.

Authors:  R J Ptachcinski; R Venkataramanan; G J Burckart
Journal:  Clin Pharmacokinet       Date:  1986 Mar-Apr       Impact factor: 6.447

9.  The kinetics of cyclosporine and its metabolites in bone marrow transplant patients.

Authors:  T L Schwinghammer; D Przepiorka; R Venkataramanan; C P Wang; G J Burckart; C S Rosenfeld; R K Shadduck
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

10.  Allogenic induction of thromboplastin synthesis in monocytes and endothelial cells. Biphasic effect of cyclosporin A.

Authors:  E Carlsen; G Gaudernack; C Filion-Myklebust; K S Pettersen; H Prydz
Journal:  Clin Exp Immunol       Date:  1989-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.